Mar 2017

PolyPid Announces Receipt of Qualified Infectious Disease Product (QIDP) Designation from FDA for D-PLEX100 in Post-Cardiac Surgery Sternal Infection

QIDP Designation Allows for FDA Priority Review and Adds Five Years of Market Exclusivity for  D-PLEX™. D-PLEX™ Currently Subject of On-going Phase Ib/II Study in Israel. Company Intends to Seek Regulatory Approvals in U.S. and Europe in Coming Year to Conduct Phase III Clinical Trial of D-PLEX™. Petah Tikva, Israel, March 08, 2017 -- PolyPid…

Read more >

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >